INFORMATION, POSTPONEMENTS, & CANCELLATIONS
• Helpful Guidelines for Remote Work – Managers & Employees.
• If you have a confirmed case of COVID-19, OR you are quarantined by a physician or governmental agency, you will need to complete the Mandatory Quarantine Absence Form.
• Any research protocol involving direct clinical benefits (infusions, injections, oral medications) to study participants will continue to be implemented in the GCRU.
• Biostatistics Drop-In Sessions have been canceled until further notice. Please contact Howard Cabral and Janice Weinberg for any statistical questions.
Community Discussion about COVID-19
The importance of engaging our local community in a discussion about COVID-19 became a priority during the pandemic. The existing partnership with three other MA CTSA’s (Tufts, Harvard, UMass) CE Programs, was leveraged to collaboratively organize a recurring COVID-19 Community Forum series.
The COVID-19 Biorepository is an institutional resource available to Boston Medical Center (BMC) and Boston University (BU) researchers interested in biologic samples collected from BMC patients. The goal of the Biorepository is to support innovative and impactful science on the SARS-CoV-2 virus. The Biorepository contains 1) discarded clinical samples from BMC patients (both patients with and without COVID-19), and 2) samples collected from a prospective cohort study of hospitalized BMC COVID-19 patients, with sample collection from ambulatory COVID-19 patient and COVID-19 survivor arms set to begin imminently.
CTSI RESPONSE TO COVID-19 PANDEMIC
Our goal was to accelerate the process of translating COVID-19 lab findings into medical practice and treatments to improve the health and well-being of a diverse patient population.
- Read the BU/BMC COVID-19 Publications
- Live COVID publication dashboard
- See listed clinical studies related to the COVID-19
PFA opens: January 5 | Town Hall: January 14 | LOI due: February 2
COVID-19 Vaccine Development: Behind the Scenes
Years of research enable a COVID-19 vaccine to be developed in record time.
Developing a vaccine and bringing it to market often takes many years. But because of work that NIH was already doing when the COVID-19 pandemic began, researchers were able to come up with vaccines for this new virus much faster.
COVID Vaccine Facts
Find answers to your questions about COVID-19 vaccines.
• What is a vaccine?
• How are Vaccines Developed?
• How will we know a vaccine is safe?
NIH COVID-19 Community Engagement Alliance (CEAL) AGAINST COVID-19 Disparities
CEAL focuses on addressing misinformation around COVID-19, engaging trusted partners and messengers in the delivery of accurate information, and educating communities on the importance of inclusion in clinical research to overcome COVID-19, and most importantly, health disparities.
Clinical trials need people from all age groups, races, ethnicities, and backgrounds. On this website, you can find information about clinical trials you can participate in as well as ways to donate blood and plasma that will lead to prevention and treatment breakthroughs to benefit everyone.
NCATS is generating a collection of datasets by screening a panel of SARS-CoV-2-related assays against all approved drugs. These datasets, as well as the assay protocols used to generate them, are being made immediately available to the scientific community on this site as these screens are completed.
N3C Data Enclave
The N3C Data Enclave is a secure platform through which the harmonized clinical data provided by our contributing members is stored. The data itself can only be accessed through a secure cloud portal hosted by NCATS and cannot be downloaded or removed. N3C invites you to begin your journey with the Enclave and join the collaborative efforts of our partners to better understand and address the most pressing COVID-19 clinical questions.
LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus. It is the most comprehensive resource on the subject, providing central access to 80588 (and growing) relevant articles in PubMed. The articles are updated daily and are further categorized by different research topics and geographic locations for improved access.
A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
COVID-19 Pandemic Information
January 05, 2021 | Tissue Model Approach Provides Clues to SARS-CoV-2 Brain Infections
The work relied on the use of brain “organoids,” tiny 3-D tissue models of human brain development. Organoids, which are developed from human stem cells, can mimic important features of a human organ’s structure and function. NCATS is developing their use to help researchers better predict the effectiveness and toxicity of compounds and drugs.
January 05, 2021 | Large Clinical Trial Will Test Combination Monoclonal Antibody Therapy for Mild/Moderate COVID-19
A Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy for its safety and efficacy in people who have mild or moderate COVID-19.
December 21, 2020 | SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests
NCI researchers and our collaborators have found that people who have had evidence of a prior infection with SARS-CoV-2, the virus that causes COVID-19, appear to have some degree of protection against being reinfected with the virus
November 22, 2020 | Pregnant Women in Third Trimester Unlikely to Pass SARS-CoV-2 Infection to Newborns
The study followed 127 pregnant women who were admitted to Boston hospitals during the spring of 2020. Among the 64 pregnant women who tested positive for SARS-CoV-2, no newborns tested positive for the virus.
November 17, 2020 | Investigational COVID-19 Therapeutics to be Evaluated in Large Clinical Trials
Two randomized, controlled Phase 3 clinical trials have begun evaluating investigational monoclonal antibodies for their safety and efficacy in treating people hospitalized with moderate COVID-19. The trials are part of the ACTIV-3 master protocol, which has an adaptive design allowing investigators to add new sub-studies of additional investigational agents.
November 16, 2020 | A Close-up of COVID-19 in Lung Cells
This colorized scanning electron microscope (SEM) image shows SARS-CoV-2-infected human lung cells (purple) covered in hair-like cilia (blue). Those cilia line the inner surface of the airways and help to clear mucus (yellow-green) containing dust and other debris from the lungs. Emerging from the surface of those infected airway cells are many thousands of coronavirus particles (red).
November 16, 2020 | The COVID-19 Vaccines: Everything You Need to Know
Two Boston University experts discuss how and when the vaccines arrive at BU and explain why COVID-19 health and safety guidelines won’t change for the spring semester.
November 16, 2020 | NIH observational study of coronavirus infection and multisystem inflammatory syndrome in children begins
The research team first collected antibodies from rhesus monkeys that had been exposed to SARS-CoV-2 and recovered. When these antibodies were injected into unexposed monkeys, the monkeys were protected against later exposure to the virus.
November 15, 2020 | NIH-funded COVID-19 home test is first to receive over-the-counter authorization from FDA
The FDA granted emergency use authorization today for an innovative COVID-19 viral antigen test developed with support from the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Initiative.
November 10, 2020 | SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention
The results were impressive. In the primary analysis, only 8 cases of Covid-19 were seen in the vaccine group, as compared with 162 in the placebo group, for an overall efficacy of 95% (with a 95% credible interval of 90.3 to 97.6%).